Skip to main content
All lobbying filings

Todd Strategy Group

Todd Strategy Group filed a Q2 termination report for Caredx, Inc. on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Caredx, Inc. · Molecular diagnostics.

As filed: TODD STRATEGY GROUP for CAREDX, INC.

All filings by Todd Strategy Group · Everything Caredx, Inc. has reported

 Filing · LD-2 quarterly report Q2 termination
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Oct 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
California
Representation ended
May 31, 2026
The registrant reported terminating its work for this client.

Official filing document

 Lobbyists on this filing 4
  • KATHERINE FLEMING COTTON
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • DANIEL M TODD
    Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
  • NICHOLAS UEHLECKE
    Previously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Medicare/Medicaid

Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.

 Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem